IP Library › Granted Patent US 12,247,078
Granted Patent B2
US 12,247,078 · App. 18/583,481 · Granted Mar 11, 2025

ERBB-2 and ERBB-3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene

Inventors: Mark Throsby (Utrecht, NL); Cecilia Anna Wilhelmina Geuijen (Utrecht, NL); David Andre Baptiste Maussang-Detaille (Utrecht, NL); Ton Logtenberg (Utrecht, NL)
Assignee: Merus N.V.
C07K16/2863C07K16/468C07K2317/21C07K2317/31C07K2317/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,247,078
App. No.
18/583,481
Granted
Mar 11, 2025
Kind
B2
Abstract

The invention relates to the field of antibodies. In particular it relates to the field of therapeutic (human) antibodies for the treatment of ErbB-2/ErbB-3 positive cells. More in particular it relates to treating of cells comprising an NRG1 fusion gene comprising at least a portion of the NRG1-gene fused to a sequence from a different chromosomal location.

Claims (23)

1. A method of treating non-small cell lung cancer or pancreatic cancer in a subject, wherein the method comprises administering to the subject a bispecific antibody that comprises a first antigen-binding site that can bind an extracellular part of ErbB-2, and a second antigen-binding site that can bind an extracellular part of ErbB-3, wherein cells of said cancer comprise an NRG1 fusion gene comprising at least a portion of the NRG1-gene fused to a sequence from a different chromosomal location;

the first antigen-binding site comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:40, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 41, and a heavy chain CDR3 comprising the amino acid sequence SEQ ID NO:42; and

the second antigen-binding site comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:54, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 55, and a heavy chain CDR3 comprising the amino acid sequence SEQ ID NO:56; and

wherein the first antigen binding site and the second antigen binding site comprise a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:75, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:76, and a light chain CDR3 comprising the amino acid sequence SEQ ID NO:77.

2. The method of claim 1 , wherein the NRG1 fusion gene comprises at least the 3′ end of the NRG1-gene fused to a 5′ sequence from a different chromosomal location.

3. The method of claim 1 , wherein the cancer is non-small cell lung cancer.

4. The method of claim 3 , wherein the non-small cell lung cancer is of the invasive mucinous adenocarcinoma subtype.

5. The method of claim 1 , wherein the cancer is pancreatic cancer.

6. The method of claim 1 , wherein the cancer is a metastasis of non-small cell lung cancer.

7. The method of claim 1 , wherein the NRG1-fusion gene expresses a protein that comprises an NRG1 EGF-like domain.

8. The method of claim 1 , wherein the NRG-fusion is a fusion of NRG1 and a gene on human chromosome 8.

9. The method of claim 8 , wherein the gene on human chromosome 8 encodes an excreted protein or a cellular membrane associated protein.

10. The method of claim 1 , wherein the NRG1 fusion gene is a fusion of the 3′ end of the NRG1-gene with the 5′ sequence of one of the genes selected from the group consisting of CD74; DOC4; TNFRSFIOB; CLU; VAMP2; SLC3A2; RBPMS; WRN; SDC4; KIF13B; SLECA2; PDE7A; ATP1B1; CDK1; BMPR1B; MCPH1 and RAB2IL1.

11. The method of claim 1 , wherein the cell is of an epithelial origin.

12. The method of claim 1 , wherein the subject has undergone a therapy targeted towards EGFR inhibition.

13. The method of claim 1 , wherein a ErbB-1 cell-surface receptor density; a ErbB-2 cell-surface receptor density; a ErbB-3 cell-surface receptor density; a ErbB-4 cell-surface receptor density, or a combination thereof on the cell has been determined.

14. The method of claim 13 , characterized in that the cell has less than 400,000 ErbB-1 cell-surface receptors per cell, or less than 200,000 ErbB-1 cell-surface receptors per cell.

15. The method of claim 1 , further comprising administering to the subject an ErbB-1 inhibitor.

16. The method of claim 15 , wherein the ErbB-1 inhibitor is cetuximab.

17. The method of claim 1 , wherein the first antigen-binding site comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:39.

18. The method of claim 1 , wherein the second antigen-binding site comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:53.

19. The method of claim 1 , wherein the first antigen binding site and the second antigen binding site comprise a light chain comprising the amino acid sequence of SEQ ID NO: 78.

20. The method of claim 1 , wherein the bispecific antibody comprises the first antigen-binding site comprising the amino acid sequence of SEQ ID NO:39, the second antigen-binding site comprising the amino acid sequence of SEQ ID NO:53, and the common light chain comprising the amino acid sequence of SEQ ID NO: 78.

Assignments (3)
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Jan 30, 2026
From: MERUS B.V.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 074562/0322 →
SECURITY INTEREST Recorded Jan 29, 2026
From: MERUS B.V.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 074532/0434 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 7, 2024
From: THROSBY, MARK; GEUIJEN, CECILIA ANNA WILHELMINA; MAUSSANG-DETAILLE, DAVID ANDRE BAPTISTE; LOGTENBERG, TON
To: MERUS N.V.
Reel/Frame 069188/0890 →
Priority Claims (1)
EP 17164292 · Mar 31, 2017 · regional
Continuity (3)
Continuation 18449460 · Aug 14, 2023
Division 16499185
Related Publication 20240182587A1 · Jun 6, 2024
References Cited (361)
US 4801687A · Ngo · 1989 [cited by applicant]
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 5151504A · Croze · 1992 [cited by applicant]
US 5731168A · Carter et al. · 1998 [cited by applicant]
US 7642228B2 · Carter et al. · 2010 [cited by applicant]
US 7705103B2 · Sherman et al. · 2010 [cited by applicant]
US 8349574B2 · Bates et al. · 2013 [cited by applicant]
US 8592562B2 · Kannan et al. · 2013 [cited by applicant]
US 8628774B2 · Gurney et al. · 2014 [cited by applicant]
US 9220775B2 · Chowdhury et al. · 2015 [cited by applicant]
US 9248181B2 · De Kruif et al. · 2016 [cited by applicant]
US 9248182B2 · De Kruif et al. · 2016 [cited by applicant]
US 9358286B2 · De Kruif et al. · 2016 [cited by applicant]
US 9551208B2 · Ma et al. · 2017 [cited by applicant]
US 9758805B2 · De Kruif et al. · 2017 [cited by applicant]
US 9914777B2 · Bakker et al. · 2018 [cited by applicant]
US 9968676B2 · Adler et al. · 2018 [cited by applicant]
US 10208354B2 · Fernandez-Cuesta et al. · 2019 [cited by applicant]
US 10358492B2 · Bakker et al. · 2019 [cited by applicant]
US 10416162B2 · Huang et al. · 2019 [cited by applicant]
US 10844127B2 · Logtenberg et al. · 2020 [cited by applicant]
US 11780925B2 · Throsby et al. · 2023 [cited by applicant]
US 20030078385A1 · Arathoon et al. · 2003 [cited by applicant]
US 20040071696A1 · Adams et al. · 2004 [cited by applicant]
US 20060212956A1 · Crocker et al. · 2006 [cited by applicant]
US 20090181022A1 · Nielsen et al. · 2009 [cited by applicant]
US 20090182127A1 · Kjaergaard et al. · 2009 [cited by applicant]
US 20090191559A1 · Huang et al. · 2009 [cited by applicant]
US 20100015133A1 · Igawa et al. · 2010 [cited by applicant]
US 20100183615A1 · Kufer et al. · 2010 [cited by applicant]
US 20100286374A1 · Kannan et al. · 2010 [cited by applicant]
US 20110077163A1 · Doranz · 2011 [cited by applicant]
US 20110195454A1 · Mcwhirter et al. · 2011 [cited by applicant]
US 20120107234A1 · Pedersen et al. · 2012 [cited by applicant]
US 20120107306A1 · Elis et al. · 2012 [cited by applicant]
US 20120270801A1 · Frejd et al. · 2012 [cited by applicant]
US 20120328623A1 · Takahashi · 2012 [cited by applicant]
US 20130071859A1 · Bates et al. · 2013 [cited by applicant]
US 20130084297A1 · Daly et al. · 2013 [cited by applicant]
US 20130115208A1 · Ho et al. · 2013 [cited by applicant]
US 20130156779A1 · Clarke et al. · 2013 [cited by applicant]
US 20130185821A1 · Babb et al. · 2013 [cited by applicant]
US 20130251703A1 · Elis et al. · 2013 [cited by applicant]
US 20130259867A1 · Amler et al. · 2013 [cited by applicant]
US 20130336885A1 · Hongo et al. · 2013 [cited by applicant]
US 20130336981A1 · De Kruif et al. · 2013 [cited by applicant]
US 20130344093A1 · Daly et al. · 2013 [cited by applicant]
US 20140056898A1 · Zhang et al. · 2014 [cited by applicant]
US 20140072579A1 · De Kruif et al. · 2014 [cited by applicant]
US 20140120096A1 · Bakker et al. · 2014 [cited by applicant]
US 20140140999A1 · De Kruif et al. · 2014 [cited by applicant]
US 20140141019A1 · Kharrat et al. · 2014 [cited by applicant]
US 20140302020A1 · Tremblay et al. · 2014 [cited by applicant]
US 20140378664A1 · Suh et al. · 2014 [cited by applicant]
US 20150013996A1 · Davies et al. · 2015 [cited by applicant]
US 20150139996A1 · De Kruif et al. · 2015 [cited by applicant]
US 20150196637A1 · De Kruif et al. · 2015 [cited by applicant]
US 20160031984A1 · Reyes et al. · 2016 [cited by applicant]
US 20160229920A1 · Ward et al. · 2016 [cited by applicant]
US 20160367699A1 · Jackson et al. · 2016 [cited by applicant]
US 20170037145A1 · Geuijen et al. · 2017 [cited by applicant]
US 20170166653A1 · Garner et al. · 2017 [cited by applicant]
US 20200247892A1 · Geuijen et al. · 2020 [cited by applicant]
US 20200291130A1 · Throsby et al. · 2020 [cited by applicant]
US 20210054096A1 · Maussang-Detaille et al. · 2021 [cited by applicant]
AU 2014212081A1 · 2015 [cited by applicant]
EP 0120694A2 · 1984 [cited by applicant]
EP 0314161A1 · 1989 [cited by applicant]
EP 0481790A2 · 1992 [cited by applicant]
EP 0523949A1 · 1993 [cited by applicant]
EP 2604625A1 · 2013 [cited by applicant]
EP 3600411A1 · 2020 [cited by applicant]
EP 3600413A1 · 2020 [cited by applicant]
JP H11500915A · 1999 [cited by applicant]
JP 2008531557A · 2008 [cited by applicant]
JP 2011508604A · 2011 [cited by applicant]
JP 2012509259A · 2012 [cited by applicant]
JP 2013511288A · 2013 [cited by applicant]
JP 2014508782A · 2014 [cited by applicant]
JP 2014511383A · 2014 [cited by applicant]
JP 2017507944A · 2017 [cited by applicant]
WO WO9627011A1 · 1996 [cited by applicant]
WO WO9850431A2 · 1998 [cited by applicant]
WO WO0063403A2 · 2000 [cited by applicant]
WO WO03004704A2 · 2003 [cited by applicant]
WO WO03107218A1 · 2003 [cited by applicant]
WO WO2004009618A2 · 2004 [cited by applicant]
WO WO2004061104A2 · 2004 [cited by applicant]
WO WO2005000894A2 · 2005 [cited by applicant]
WO WO2005118635A2 · 2005 [cited by applicant]
WO WO2006028936A2 · 2006 [cited by applicant]
WO WO2006044908A2 · 2006 [cited by applicant]
WO WO2006091209A2 · 2006 [cited by applicant]
WO WO2006106905A1 · 2006 [cited by applicant]
WO WO2007110205A2 · 2007 [cited by applicant]
WO WO2007147901A1 · 2007 [cited by applicant]
WO WO2008027236A2 · 2008 [cited by applicant]
WO WO2008100624A2 · 2008 [cited by applicant]
WO WO2008119353A1 · 2008 [cited by applicant]
WO WO2008140493A2 · 2008 [cited by applicant]
WO WO2009051974A1 · 2009 [cited by applicant]
WO WO2009080251A1 · 2009 [cited by applicant]
WO WO2009080252A1 · 2009 [cited by applicant]
WO WO2009080253A1 · 2009 [cited by applicant]
WO WO2009089004A1 · 2009 [cited by applicant]
WO WO2009098596A2 · 2009 [cited by applicant]
WO WO2009157771A2 · 2009 [cited by applicant]
WO WO2010022736A2 · 2010 [cited by applicant]
WO WO2010059315A1 · 2010 [cited by applicant]
WO WO2010084197A1 · 2010 [cited by applicant]
WO WO2010108127A1 · 2010 [cited by applicant]
WO WO2010129304A2 · 2010 [cited by applicant]
WO WO2010151792A1 · 2010 [cited by applicant]
WO WO2011022727A2 · 2011 [cited by applicant]
WO WO2011028952A1 · 2011 [cited by applicant]
WO WO2011028953A1 · 2011 [cited by applicant]
WO WO2011143545A1 · 2011 [cited by applicant]
WO WO2012023053A2 · 2012 [cited by applicant]
WO WO2012058768A1 · 2012 [cited by applicant]
WO WO2012116317A2 · 2012 [cited by applicant]
WO WO2012125573A2 · 2012 [cited by applicant]
WO WO2012125864A2 · 2012 [cited by applicant]
WO WO2012131555A2 · 2012 [cited by applicant]
WO WO2013048883A2 · 2013 [cited by applicant]
WO WO2013084151A2 · 2013 [cited by applicant]
WO WO2013134686A1 · 2013 [cited by applicant]
WO WO2013149159A1 · 2013 [cited by applicant]
WO WO2013157953A1 · 2013 [cited by applicant]
WO WO2013157954A1 · 2013 [cited by applicant]
WO WO2014051433A1 · 2014 [cited by applicant]
WO WO2014060365A1 · 2014 [cited by applicant]
WO WO2014081954A1 · 2014 [cited by applicant]
WO WO2014159580A1 · 2014 [cited by applicant]
WO WO2014165855A1 · 2014 [cited by applicant]
WO WO2014182970A1 · 2014 [cited by applicant]
WO WO2015130172A1 · 2015 [cited by applicant]
WO WO2015130173A1 · 2015 [cited by applicant]
WO WO2016077734A2 · 2016 [cited by applicant]
WO WO2016090024A2 · 2016 [cited by applicant]
WO WO2016201454A1 · 2016 [cited by applicant]
WO WO2017069628A2 · 2017 [cited by applicant]
WO WO2018182422A1 · 2018 [cited by applicant]
Adelaïde, J., et al., “A Recurrent Chromosome Translocation Breakpoint in Breast and Pancreatic Cancer Cell Lines Targets the Neuregulin/NRG1 Gene,” Genes Chromosome Cancer, 37(4):333-345, Wiley-Liss, Inc, United States… [cited by applicant]
Agus, D.B., et al., “Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth,” Cancer Cell, 2(2):127-137, Cell Press, United States (Aug. 2002). [cited by applicant]
Balko, J.M., et al., “The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium,” PNAS, 109(1):221-226, U.S. National Academy of Science, United States (Jan. 2012). [cited by applicant]
Birnbaum, D., et al., “Chromosome arm 8p and cancer: a fragile hypothesis,” The Lancet Oncology, 4:639-642, Elsevier, Netherlands (Oct. 2003). [cited by applicant]
Chua, Y.L., et al., “The NRG1 gene is frequently silenced by methylation in breast cancers and is a strong candidate for the 8p tumor suppressor gene,” Oncogene, 28(46):4041-4052, Macmillan Publishers Limited, Germany (… [cited by applicant]
Cooke, S.L., et al., “High-resolution array CGH clarifies events occurring on 8p in carcinogenesis,” BMC Cancer, 8(288):1-15, BioMed Central Ltd., United Kingdom (Oct. 2008). [cited by applicant]
Duruisseaux, M., et al., “NRG1 fusion in a French cohort of invasive mucinous lung adenocarcinoma,” Cancer Medicine, 5(12):3579-3585, John Wiley & Sons Ltd., United States (Dec. 2016). [cited by applicant]
Falls, D.L., “Neuregulins: functions, form, and signaling strategies,” Exp Cell Res, 284:14-30, Elsevier, Netherlands (Mar. 2003). [cited by applicant]
Fernandez-Cuesta, L., et al., “Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer,” Clinical Cancer Research, 21(9):1989-1994, American Association for Cancer Research, United States (May 2015). [cited by applicant]
Fernandez-Cuesta, L., et al., “CD74-NRG1 Fusions in Lung Adenocarcinoma,” Cancer Discovery, 4(4):415-422, American Association for Cancer Research, United States (Apr. 2014). [cited by applicant]
Gaborit, N., et al., “Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3,” Human Vaccines and Immunotherapies, 12(3):576-592, Taylor & Francis, United Kingdom (Mar. 2015). [cited by applicant]
Geuijen, C., et al., “Abstract LB-261: Mechanism of action of MCLA-128, a humanized bispecific IgG1 antibody targeting the HER2: HER3 heterodimer,” Cancer Research; 106 [cited by applicant]
Hayes, N.V.L., and Gullick, W.J., “The Neuregulin Family of Genes and their Multiple Splice Variants in Breast Cancer,” J. Mammary Gland Biol Neoplasia, 13(205):214, Springer, United States (Jun. 2008). [cited by applicant]
International Search Report for International Application No. PCT/NL2018/050206, European Patent Office, Netherlands, mailed on Jun. 22, 20018, 4 pages. [cited by applicant]
Jung, Y., et al., “VAMP2-NRG1 Fusion Gene is a Novel Oncogenic Driver of Non-Small-Cell Lung Adenocarcinoma,” J Thor Oncol 10(7): 1107-1111, International Association for the Study of Lung Cancer, United States (Jul. 20… [cited by applicant]
Junttila, T.T., et al., “Ligand-Independent HER2/HER3/PI3K Complex is Disrupted by Trastuzumab and is Effectively Inhibited by the PI3K Inhibitor GDC-0941,” Cancer Cell, 15(5):429-440, Elsevier, Netherlands (May 2009). [cited by applicant]
Junttila, T.T., et al., “Superior In vivi Efficacy of Afucosylated Trastuzumab in the Treatment of HER2-Amplified Breast Cancer,” Cancer Research, 70(11):4481-4489, American Association for Cancer Research, United State… [cited by applicant]
Le Clorennec, C., et al., “Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9 F7-F11 by Increasing its Binding to HER3,” Molecular Cancer Therapeutics, 16(7):1312-1323, A… [cited by applicant]
Lee-Hoeflich, S.T., et al., “A Central Role for HER3 in HER2-Amplified Breast Cancer: Implications for Targeted Therapy,” Cancer Research, 68(14):5878-5887, American Association for Cancer Research, United States (Jul. … [cited by applicant]
Malm, M., et al., “Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds,” MABS 8(7): 1195-1209, Taylor & Frances, United Kingdom (Oct. 2016). [cited by applicant]
Merchant, M.A., et al., “An efficient route to human bispecific IgG,” Nature Biotechnology, 16: 677-681, Nature Publishing Group, United States (Jul. 1998). [cited by applicant]
De Nardis, C., et al., “A new approach for generation bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G1,” Journal of Biological Chemistry, 292(35):14706-14… [cited by applicant]
Ocana, A., et al., “HER3 Overexpression and Survival in Solid Tumors: A Meta-Analysis,” J Natl Cancer Inst, 105(4):266-273, Oxford University Press, United Kingdom (Feb. 2013). [cited by applicant]
Pole, J.C.M., et al., High-resolution analysis of chromosome rearrangements on 8p in breast, colon and pancreatic cancer reveals a complex pattern of loss, gain and translocation, Oncogene, 25:5693-5706, Nature Publishi… [cited by applicant]
Sanchez-Valdivieso, E.A., et al., “y-Heregulin has no biological significance in primary breast cancer,” British Journal of Cancer, 86(8):1362-1366, Cancer Research UK, United Kingdom (Apr. 2002). [cited by applicant]
Schoeberl, B., et al., “An ErB3 Antibody, MM-121, is Active in Cancers with Ligand-Dependent Activation,” Cancer Research, 70(6):2485-2494, American Association for Cancer Research, United States (Mar. 2010). [cited by applicant]
Sergina, N.V., et al., “Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3,” Nature, 445(7126):437-441, Springer, United Kingdom (Jan. 2007). [cited by applicant]
Weinstein, E.J., et al., “The oncogene heregulin induces apoptosos in breast wpithelial cells and tumors,” Oncogene, 17:2107-2113, Stockton Press, United Kingdom (Oct. 1998). [cited by applicant]
Wilson, T.R., et al., “Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors,” Nature, 487(7408):505-509, Springer, United Kingdom (Jul. 2012). [cited by applicant]
Wilson, T.R., et al., “Neuregulin-1-Mediated Autocrine Signaling Underlies Sensitivity to HER2 Kinase Inhibitors in a Subset of Human Cancer,” Cancer Cells, 20(2):158-172, Elsevier, Inc., Netherlands (Aug. 2011). [cited by applicant]
Yarden, Y. et al., “The ERBB network: at last, cancer therapy meets systems biology,” Nat Rev Cancer, 12:553-563, Macmillan Publishers, Limited, United Kingdom (Jul. 2012). [cited by applicant]
Zhang, H., et al., “ErbB receptors: from oncogenes to targeted cancer therapies,” J Clin Invest, 117(8):2051-2058, The American Society for Clinical Investigations, United States (Aug. 2007). [cited by applicant]
125084 Erbitux Pharmacology Review Part 2—FDA, 31 pages. [cited by applicant]
Zhu, Z., et al., “Remodeling Domain Interfaces to Enhance Heterodimer Formation,” Protein Science 6(4):781-788, Cold Spring Harbor Laboratory Press, United States (Apr. 1997). [cited by applicant]
Almagro, J.C. and Fransson, J., “Humanization of Antibodies,” Frontiers in Bioscience 13:1619-1633, Frontiers in Bioscience Publications, United States (Jan. 2008). [cited by applicant]
Appella, E , et al., “Structure and Function of Epidermal Growth Factor-Like Regions in Proteins,” FEBS Letters 231(1):1-4, John Wiley & Sons Ltd, United Kingdom (Apr. 1988). [cited by applicant]
Ardeshirpour, Y., et al., “In vivo assessment of HER2 receptor density in HER2-positive tumors by near-infrared imaging, using repeated injections of the fluorescent probe,” Technology In Cancer Research & Treatment 13(… [cited by applicant]
Arteaga, C.L., et al., “Treatment of Her2-positive Breast Cancer: Current Status and Future Perspectives,” Nature Reviews Clinical Oncology 9(1):16-32, Nature Publishing Group, United Kingdom (Nov. 2011). [cited by applicant]
Schaefer, G., et al., “A Two-in-one Antibody Against Her3 and Egfr Has Superior Inhibitory Activity Compared With Monospecific Antibodies,” Cancer Cell 20(4):472-486, Cell Press, United States (Oct. 2011). [cited by applicant]
Bargou, R., et al., “Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-engaging Antibody,” Science 321(5891):974-977, American Association for the Advancement of Science, United States (Aug. 2008). [cited by applicant]
Barthelemy, P.A., et al., “Comprehensive Analysis of the Factors Contributing to the Stability and Solubility of Autonomous Human Vh Domains,” The Journal of Biological Chemistry 283:3639-3654, American Society for Bioc… [cited by applicant]
Baselga, J., et al., “Pertuzumab Plus Trastuzumab Plus Docetaxel for Metastatic Breast Cancer,” The New United Kingdom Journal of Medicine 366(2):109-119, Massachusetts Medical Society, United States (Jan. 2012). [cited by applicant]
Beiboer, S.H., et al., “Guided Selection of a Pan Carcinoma Specific Antibody Reveals Similar Binding Characteristics yet Structural Divergence between the Original Murine Antibody and its Human Equivalent,” Journal of … [cited by applicant]
Birchmeier, C., et al., “Met, Metastasis, Motility and More,” Nature Reviews Molecular Cell Biology 4(12):915-925, Nature Publishing Group, United Kingdom (Dec. 2003). [cited by applicant]
Blomquist, M.C., et al., “Vaccinia Virus 19-Kilodalton Protein: Relationship to Several Mammalian Proteins, Including Two Growth Factors,” Proceedings of the National Academy of Sciences of the United States of America … [cited by applicant]
Bostrom, J., et al., “Variants of the Antibody Herceptin that Interact with HER2 and VEGF at the Antigen Binding Site,” Science 323(5921):1610-1614, American Association for the Advancement of Science, United States (Ma… [cited by applicant]
Boyer, C.M., et al., “Relative Cytotoxic Activity of Immunotoxins Reactive With Different Epitopes on the Extracellular Domain of the C-Erbb-2 (Her-2/Neu) Gene Product P185,” International Journal of Cancer 82(4):525-53… [cited by applicant]
Strelkauskas, A., et al., “Human Monoclonal Antibody: 2. Simultaneous Expression of lgG and lgM with Similar Binding Specificities by a Human Hybrid Clone,” Hybridoma 6(5):479-488, Mary Ann Liebert, United States (Oct. … [cited by applicant]
Zhao, X., et al., “Targeting C-type Lectin-like Molecule-1 for Antibody-mediated Immunotherapy in Acute Myeloid Leukemia,” Haematologica 95(1):71-78, Ferrata Storti Foundation, Italy (Jan. 2010). [cited by applicant]
Selzer, T., et al., “Rational Design of Faster Associating and Tighter Binding Protein Complexes,” Nature Structural & Molecular Biology 7(7):537-541, Nature Publishing Group, United States (Jul. 2000). [cited by applicant]
Carter, P., “Bispecific Human IgG by Design,” Journal of Immunological Methods 248(1-2):7-15, Elsevier, Netherlands (Feb. 2001). [cited by applicant]
Carter, P., et al., “Toward the Production of Bispecific Antibody Fragments for Clinical Applications,” Journal of Hematotherapy 4:463-470, Mary Ann Liebert, Inc., United States (Oct. 1995). [cited by applicant]
Castoldi, R., et al., “A Novel Bispecific EGFR/Met Antibody Blocks Tumor-promoting Phenotypic Effects Induced by Resistance to EGFR Inhibition and Has Potent Antitumor Activity,” Oncogene 32(50):5593-5601, Nature Publis… [cited by applicant]
Chames, P., and Baty, D., “Bispecific Antibodies for Cancer Therapy: The Light at the End of the Tunnel?,” MAbs 1(6):539-547, Taylor & Francis, United States (Nov.-Dec. 2009). [cited by applicant]
Chandra, A., “The Role of ERBB3 Inhibitors as Cancer Therapeutics,” Boston University, 1-78 (May 2015). [cited by applicant]
Chen, C.T., et al., “MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells,” Molecular Cancer Therapeutics 11(3):650-669, American Association for Cancer Research, Inc., Unite… [cited by applicant]
Chernomordik, V., et al., “Quantitative Analysis of HER2 Receptor Expression in Vivo By Near-Infrared Optical Imaging,” Molecular Imaging 9(4):192-200, Sage Publications, United States (Aug. 2010). [cited by applicant]
Schlom, J., et al., “Therapeutic Advantage of High-affinity Anticarcinoma Radioimmunoconjugates,” Cancer Research 52(5):1067-1072, American Association for Cancer Research, United States (Mar. 1992). [cited by applicant]
Clarke, M.F., et al., “Cancer stem cells—perspectives on current status and future directions: AACR Workshop on cancer stem cells,” Cancer Research 66(19):9339-9344, American Association for Cancer Research, United Stat… [cited by applicant]
Cochran, J.R., et al., “Domain-level Antibody Epitope Mapping Through Yeast Surface Display of Epidermal Growth Factor Receptor Fragments,” Journal of Immunology Methods 287(1-2):147-158, Elsevier, Netherland (Apr. 2004… [cited by applicant]
Conforti, F., et al., “Dissecting Breast Cancer Complexity: Specific Biological Features and Vulnerabilities of Triple Positive Breast Cancer Tumors,” Clinic of Oncology 2(1288):1-3, Remedy Publications LLC, United Stat… [cited by applicant]
Corada, M., et al., “Monoclonal Antibodies Directed To Different Regions of Vascular Endothelial Cadherin Extracellular Domain Affect Adhesion and Clustering of the Protein and Modulate Endothelial Permeability,” Blood … [cited by applicant]
Corona S.P., et al., “CDK4/6 Inhibitors in HER2-positive Breast Cancer,” Critical Reviews in Oncology/Hematology 118:208-214, Elsevier, Netherlands (Apr. 2017). [cited by applicant]
Curley, M.D., et al., “Seribantumab, An Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor-Positive Breast Cancer Model,” Molecular Cancer Therapeutics 14(1… [cited by applicant]
Davis, C.G., “The Many Faces of Epidermal Growth Factor Repeats,” The New Biologist 2(5):410-419, W.B. Saunders Co., United States (May 1990). [cited by applicant]
Davis, J.H., et al., “SEEDbodies: Fusion Proteins Based on Strand-exchange Engineered Domain (SEED) CH3 Heterodimers in an Fc Analogue Platform for Asymmetric Binders or Immunofusions and Bispecific Antibodies,” Protein… [cited by applicant]
De Genst, E., et al., “Antibody Repertoire Development in Camelids,” Developmental and Comparative Immunology 30(1-2):187-198, Elsevier Science, United States (2006). [cited by applicant]
De Goeij, B.E., et al., “Efficient Payload Delivery by a Bispecific Antibody-Drug Conjugate Targeting HER2 and CD63,” Molecular Cancer Therapeutics 5(11):2688-2697, American Association for Cancer Research, United State… [cited by applicant]
De Kruif, J., et al., “Selection and Application of Human Single Chain Fv Antibody Fragments from a Semi-Synthetic Phage Antibody Display Library with Designed CDR3 Regions,” Journal of Molecular Biology 248(1):97-105, … [cited by applicant]
De Kruif, J., et al., “Generation of Stable Cell Clones Expressing Mixtures of Human Antibodies,” Biotechnology and Bioengineering 106(5):741-750, Wiley, United States (Aug. 2010). [cited by applicant]
Zhang, B., et al., “Abstract 655: Combination of Mm-111, an Erbb2/erbb3 Bispecific Antibody, With Endocrine Therapies as an Effective Strategy for Treatment of Er+/her2+ Breast Cancer,” Cancer Research 71(8):655-655, Am… [cited by applicant]
Schmitz, K., and Ferguson K.M., “Interaction of Antibodies With ErbB Receptor Extracellular Regions,” Experimental Cell Research 315(4):659-670, Academic Press, United States (Feb. 2009). [cited by applicant]
De Pascalis, R., et al., “Grafting of ‘Abbreviated’ Complementarity-determining Regions Containing Specificity-determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibo… [cited by applicant]
De Vries, S.J., et al., “The HADDOCK Web Server for Data-driven Biomolecular Docking,” Nature Protocols 5(5):883-897, Nature Publishing Group, United Kingdom (May 2010). [cited by applicant]
Dhanasekaran S.M., et al., “Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes,” Nature Communications 5:5893, Springer Nature, Germany (Dec. 2014). [cited by applicant]
Seidel, C., et al., “Role of hepatocyte growth factor and its receptor c-met in multiple myeloma,” Medical Oncology 15:145-153, Springer Nature, Switzerland AG (Sep. 1998). [cited by applicant]
Doolittle, R.F., et al., “Computer-Based Characterization of Epidermal Growth Factor Precursor,” Nature 307(5951):558-560, Nature Publishing Group, United Kingdom (Feb. 1984). [cited by applicant]
Dreier, T., et al., “Extremely Potent, Rapid and Costimulation-Independent Cytotoxic T-Cell Response against Lymphoma Cells Catalyzed by a Single-Chain Bispecific Antibody,” International Journal of Cancer 100(6):690-69… [cited by applicant]
Zhang, Y.W., et al., “MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth,” Cancer Research 70(17… [cited by applicant]
Ewer, M.S., et al., “Cardiotoxicity of Anticancer Treatments: What the Cardiologist Needs to Know,” Nature Reviews Cardiology 7(10):564-575, Nature Publishing Group, United Kingdom (Oct. 2010). [cited by applicant]
Ferguson, K.M., “Structure-based View of Epidermal Growth Factor Receptor Regulation,” Annual Review of Biophysics 37:353-373, Annual Reviews, United States (2008). [cited by applicant]
Fong, J.T., et al., “Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer,” PLoS One 8(11):e78398, Public Library of Science, U… [cited by applicant]
Freeman D., et al., “Panitumumab and Cetuximab Epitope Mapping and in Vitro Activity,” Journal of Clinical Oncology 26(15):14536-14536, American Society of Clinical Oncology, United States (May 2008). [cited by applicant]
Fu, W., et al., “Insights into HER2 signaling from step-by-step optimization of anti-HER2 antibodies,” MAbs 6(4):978-990, Taylor & Francis, United Kingdom (Jul.-Aug. 2014). [cited by applicant]
Shames, D.S., et al., “High Heregulin Expression is Associated with Activated HER3 and May Define an Actionable Biomarker in Patients with Squamous Cell Carcinomas of the Head and Neck,” PLoS One 8(2):e56765, Public Lib… [cited by applicant]
Garrett, T.P., et al., “Crystal Structure of a Truncated Epidermal Growth Factor Receptor Extracellular Domain Bound to Transforming Growth Factor alpha,” Cell 110(6):763-773, Cell Press, United States (Sep. 2002). [cited by applicant]
Wolff, A.C., et al., “Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update,” Jo… [cited by applicant]
Woning, S.V.D., et al., “Quantification of ErbB3 Receptor Density on Human Breast Cancer Cells, Using a Stable Radio-Labeled Mutant of Nrglbeta,” Biochemical and Biophysical Research Communications, 378(2):285-289, Else… [cited by applicant]
Xu, F., et al., “Antibody-Induced Growth Inhibition is Mediated Through Immunochemically and Functionally Distinct Epitopes on the Extracellular Domain of the c-erB-2 (HER-2/neu) Gene Product p185,” International Journa… [cited by applicant]
Yano, S. et al., “Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma With Epidermal Growth Factor Receptor-activating Mutations,” Cancer Research 68(22):9479-9487, American Association for Canc… [cited by applicant]
Yano, S., et al., “Molecular Mechanism of EGFR-TKI Resistance,” Japanese Journal of Lung Cancer 49(6):939-943, The Japan Lung Cancer Society, Japan (Oct. 2009). [cited by applicant]
Yarden, Y. et al., “The EGFR family and its ligands in human cancer: signaling mechanisms and therapeutic opportunities,” European Journal of Cancer 37(Supp4):S3-S8, Elsevier, Netherlands (Sep. 2001). [cited by applicant]
Yarden, Y., et al., “The ERBB Network: At Last, Cancer Therapy Meets Systems Biology,” Nature Reviews Cancer 12(8):553-563, Nature Publishing Group, United Kingdom (Jul. 2012). [cited by applicant]
Yonesaka, K., et al., “Activation of ERBB2 Signaling Causes Resistance to the Egfr-Directed Therapeutic Antibody Cetuximab,” Science Translational Medicine 3(99):99ra86, American Association for the Advancement of Scien… [cited by applicant]
Yu, H., et al., “Plasma Levels of Insulin-like Growth Factor-I and Lung Cancer Risk: A Case- control Analysis,” Journal of the National Cancer Institute 91(2):151-156, Oxford University Press, United States (Jan. 1999). [cited by applicant]
Uberall, I., et al., “The status and role of ErbB receptors in human cancer,” Experimental and Molecular Pathology 84:79-89, Elsevier, Netherlands (Apr. 2008). [cited by applicant]
U.S. Appl. No. 61/635,935, inventor Kruif; C.A.D, filed Apr. 20, 2012. [cited by applicant]
Vajdos, F.F., et al., “Comprehensive Functional Maps of the Antigen-binding Site of an Anti-Erbb2 Antibody Obtained with Shotgun Scanning Mutagenesis,” Journal of Molecular Biology 320(2):415-428, Academic Press, United… [cited by applicant]
Vecchione, L., et al., “EGFR-targeted therapy,” Experimental Cell Research 317(19):2765-2771, Academic Press, United States (Nov. 2011). [cited by applicant]
Geuijen, C.A.W., et al., “Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade,” Cancer Cell 33(5):922-936, Elsevier, Netherlands (May 2018). [cited by applicant]
Sheridan, C., “Amgen Swallows Micromet to BiTE Into All Market,” Nature Biotechnology 30(4):300-301, Nature America Publishing, United States (Apr. 2012). [cited by applicant]
Girlanda, S., et al., “MICA Expressed by Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance Plasma Cells Costimulates Pamidronate-activated Gammadelta Lymphocytes,” Cancer Research, 65(16):7502-7508… [cited by applicant]
Greco, W.R., et al., “The Search for Synergy: a Critical Review From a Response Surface Perspective,” Pharmacological Reviews 47(2):331-385, American Society for Pharmacology and Experimental Therapeutics, United States… [cited by applicant]
Gulli, L.F., et al., “Epidermal Growth Factor-induced Apoptosis in A431 Cells can be Reversed by Reducing the Tyrosine Kinase Activity,” Cell Growth & Differentiation 7(2):173-178, The Association, United States (Feb. 1… [cited by applicant]
Gunasekaran, K., et al., “Enhancing Antibody Fc Heterodimer Formation Through Electrostatic Steering Effects: Applications to Bispecific Molecules and Monovalent IgG,” Journal of Biological Chemistry 285(25):19637-19646… [cited by applicant]
Gussow, D., and Seemann, G., “Humanization of Monoclonal Antibodies,” Methods in Enzymology 203:99-121, Elsevier Science, United States (1991). [cited by applicant]
Shiraiwa H., et al., “Engineering a Bispecific Antibody With a Common Light Chain: Identification and Optimization of an Anti-cd3 Epsilon and Anti-GPC3 Bispecific Antibody, Ery974,” Methods 154:10-20, Academic Press, Un… [cited by applicant]
Hammond, M.E.H., et al., “American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer,” Journa… [cited by applicant]
Siegfried, J.M., et al., “The clinical significance of hepatocyte growth factor for non-small cell lung cancer,” The Annals of Thoracic Surgery 66(6):1915-1918, Elsevier, Netherlands (Dec. 1998). [cited by applicant]
Harms B., et al., “Understanding the Role of Cross-arm Binding Efficiency in the Activity of Monoclonal and Multispecific Therapeutic Antibodies”, Methods 65(1):95-104, Elsevier, Netherlands (Jan. 2014). [cited by applicant]
Hathaway, H.J., et al., “Detection of breast cancer cells using targeted magnetic nanoparticles and ultra-sensitive magnetic field sensors,” Breast Cancer Research 13(5):R108, BioMed Central, United Kingdom (Nov. 2011). [cited by applicant]
Hendsch, Z.S., et al., “Preferential Heterodimer Formation via Undercompensated Electrostatic Interactions,” Journal of the American Chemical Society 123(6):1264-1265, American Chemical Society, United States (Feb. 2001… [cited by applicant]
Hommel, U., et al., “Human Epidermal Growth Factor. High Resolution Solution Structure and Comparison With Human Transforming Growth Factor Alpha,” Journal of Molecular Biology 227(1):271-282, Elsevier, United Kingdom (… [cited by applicant]
Sinha, N., et al., “Differences in Electrostatic Properties at Antibody-antigen Binding Sites: Implications for Specificity and Cross-reactivity,” Biophysical Journal 83(6):2946-2968, Cambridge, United States (Dec. 2002… [cited by applicant]
Hu, T., and Li, C., “Convergence between Wnt-B-catenin and EGFR signaling in cancer,” Molecular Cancer 236:1-7, BioMed Central, United States (Sep. 2010). [cited by applicant]
Huang W, et al., “Comparison of Central HER2 Testing With Quantitative Total HER2 Expression and HER2 Homodimer Measurements Using a Novel Proximity-Based Assay,” American Journal of Clinical Pathology 134(2):303-311, O… [cited by applicant]
Huhalov, A., et al., “MM-111, an ErbB2/ErbB3 Bispecific Antibody with Potent Activity in ErbB2-Overexpressing Cells, Positively Combines with Trastuzumab to Inhibit Growth of Breast Cancer Cells Driven by the ErbB2/ErbB… [cited by applicant]
Idusogie, E.E., et al., “Mapping of the Clq Binding Site on Rituxan, A Chimeric Antibody with a Human IgG1 Fc,” The Journal of Immunology 164(8):4178-4184, American Association of Immunologists, United States (Apr. 2000… [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/NL2018/050329, European Patent Office, Netherlands, mailed on Sep. 17, 2018, 10 pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/NL2018/050205, European Parent Office, Netherlands, mailed on Sep. 10, 2018, 23 pages. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/NL2016/050726, The International Bureau of WIPO, mailed on Apr. 24, 2018, 13 pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/NL2018/050537, European Patent Office, Netherlands, mailed on Jan. 30, 2019, European Patent Office, Rijswijk, Netherlands, 19 pages. [cited by applicant]
International Search Report and Written Opinion for International Application No., PCT/NL2018/050204, European Patent Office, Netherlands, mailed on Jun. 25, 2018, 16 pages. [cited by applicant]
International search report and written opinion for International Application No. PCT/NL2016/050726, European Patent Office, Netherlands, mailed Jun. 2, 2017, 20 pages. [cited by applicant]
Jackson, C., et al., “Clinical Significance of HER-2 Splice Variants in Breast Cancer Progression and Drug Resistance,” International Journal of Cell Biology 2013:973584, Hindawi, United Kingdom (Jul. 2013). [cited by applicant]
Zolot, R.S., et al., “Antibody-Drug Conjugates,” Nature Reviews Drug Discovery 12(4):259-260, Nature Publishing Group, United Kingdom (Apr. 2013). [cited by applicant]
Sinha, N., et al., “Electrostatics in Protein Binding and Function,” Current Protein and Peptide Science 3(6):601-614, Bentham Science Publishers, Netherlands (Dec. 2002). [cited by applicant]
Jelovac, D., et al., “HER2-Directed Therapy for Metastatic Breast Cancer,” Oncology (Williston Park) 27(3):166-175, CMP Healthcare Media, United States (Mar. 2013). [cited by applicant]
Ji, H., et al., “Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors,” PNAS 103(20):7817-7822, United States National Academy of Sciences, United St… [cited by applicant]
Jiang, B., et al., “A Novel Peptide Isolated from a Phage Display Peptide Library with Trastuzumab can Mimic Antigen Epitope of HER-2,” The Journal of Biological Chemistry 280(6):4656-4662, The American Society for Bioc… [cited by applicant]
Jin, H., et al., “Metmab, the One-Armed 5D5 Anti-C-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival,” Cancer Research 68(11):4360-4368, American Association for Cancer Research, United Sta… [cited by applicant]
Jorissen, R.N., et al., “Epidermal Growth Factor Receptor: Mechanisms of Activation and Signaling,” Experimental Cell Research 284(1):31-53, Academic Press, United States (Mar. 2003). [cited by applicant]
Kabat, E.A., et al., “Identical V Region Amino Acid Sequences and Segments of Sequences in Antibodies of Different Specificities. Relative Contributions of Vh and V1 Genes, Minigenes, and Complementarity-determining Reg… [cited by applicant]
Kang J.C., et al., “Engineering Multivalent Antibodies to Target Heregulin-Induced HER3 Signaling in Breast Cancer Cells,” MAbs 6(2):340-353, Taylor & Francis, United Kingdom (Apr. 2014). [cited by applicant]
Kim, G.P., et al. “Targeting Colorectal Cancer with Human Anti-EGFRMonoclonocal Antibodies: Focus on Panitumumab,” Biologics 2(2):223-228, Dove Medical Press, New Zealand (Jun. 2008). [cited by applicant]
Soltoff, S.P., et al., “ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor,” Molecular and Cellular Biology 14(6):3550-3558, American Society for Microbiology, United States (Jun… [cited by applicant]
Kim, K.H., et al., “Progress of Antibody-Based Inhibitors of the Hgf-Cmet Axis in Cancer Therapy,” Experimental & Molecular Medicine 49(3):e307, Nature Publishing Group, United States (Mar. 2017). [cited by applicant]
Kipriyanov, S.M., et al., “Bispecific CD3 x CD19 Diabody for T Cell-Mediated Lysis of Malignant Human B Cells,” International Journal of Cancer 77(5):763-772, Wiley-Liss, United States (Aug. 1998). [cited by applicant]
Klein, C., et al., “Progress in Overcoming the Chain Association Issue in Bispecific Heterodimeric IgG Antibodies,” MAbs 4(6):653-663, Taylor & Francis, United States (Nov.-Dec. 2012). [cited by applicant]
Kodack D.P., et al., “Combined Targeting of HER2 and VEGFR2 for Effective Treatment of HER2-amplified Breast Cancer Brain Metastases,” Proceedings of the National Academy of Sciences 109(45):E3119-E3127, United States N… [cited by applicant]
Koide, A., et al., “The Fibronectin Type III Domain as a Scaffold for Novel Binding Proteins,” Journal of Molecular Biology 284(4):1141-1151, Academic Press, United States (Dec. 1998). [cited by applicant]
Kol, A., et al., “HER3, Serious Partner in Crime: Therapeutic Approaches and Potential Biomarkers for Effect of HER3-targeting,” Pharmacology & Therapeutics 143(1):1-11, Pergamon Press, United Kingdom (Jul. 2014). [cited by applicant]
Kontermann, R.E., “Dual Targeting Strategies with Bispecific Antibodies,” MAbs 4(2):182-197, Taylor and Francis, United States (Mar.-Apr. 2012). [cited by applicant]
Sorkin, A., “Internalization of the Epidermal Growth Factor Receptor: Role in Signaling,” Biochemical Society Transactions 29(Pt 4): 480-484, Portland Press on the Behalf of the Biochemical Society, United Kingdom (Aug.… [cited by applicant]
Kruif, D.J., et al., “Human Immunoglobulin Repertoires Against Tetanus Toxoid Contain a Large and Diverse Fraction of High-affinity Promiscuous V(H) Genes,” Journal of Molecular Biology 387(3):548-558, Elsevier, United … [cited by applicant]
Spiess, C., et al., “Alternative Molecular Formats and Therapeutic Applications for Bispecific Antibodies,” Molecular Immunology 67(2 Pt A):95-106, Pergamon Press, United Kingdom (Oct. 2015). [cited by applicant]
Kubota, T., et al., “Engineered therapeutic antibodies with improved effector functions,” Cancer Science 100(9):1566-1572, Wiley Publishing on behalf of the Japanese Cancer Association, United Kingdom (Sep. 2009). [cited by applicant]
Kulkarni-Kale, U., et al., “CEP: a Conformational Epitope Prediction Server,” Nucleic Acids Research 33:W168-W171, Oxford University Press, United Kingdom (Jul. 2005). [cited by applicant]
Landgraf, R., et al., “HER2 Therapy. HER2 (ERBB2): Functional Diversity from Structurally Conserved Building Blocks,” Breast Cancer Research 9(1):202, BioMed Central Ltd, United Kingdom (2007). [cited by applicant]
Lazrek, Y., et al., “Anti-HER3 Domain 1 and 3 Antibodies Reduce Tumor Growth by Hindering HER2/HER3 Dimerization and AKT-Induced MDM2. Xiap, and Fox1 Phosphorylation,” Neoplasia 15(3):335-347, Neoplasia Press, United St… [cited by applicant]
Le Gall, F., et al., “Effect of Linker Sequences Between the Antibody Variable Domains on the Formation, Stability and Biological Activity of a Bispecific Tandem Diabody,” Protein Engineering, Design & Selection 17(4):3… [cited by applicant]
Ledon, N., et al., “Comparative Analysis of Binding Affinities to Epidermal Growth Factor Receptor of Monoclonal Antibodies Nimotuzumab and Cetuximab Using Different Experimental Animal Models,” Placenta 32:531-534, Els… [cited by applicant]
Lee, D., et al., “Development of antibody-based c-Met inhibitors for targeted cancer therapy,” Immunotargets and Therapy 9(4):34-44, Dove Medical Press, New Zealand (Feb. 2015). [cited by applicant]
Lee, H.J., et al., “Gemini Vitamin D Analog Suppresses Erbb2-positive mammary tumor growth via inhibition of ErbB2/AKT/ERK Signaling,” Journal of Steroid Biochemistry and Molecular Biology 121(1-2):408-412 Elsevier Scie… [cited by applicant]
Li, S., et al., “Structural basis for inhibition of the epidermal growth factor receptor by cetuximab,” Cancer Cell 7(4):301-311, Elsevier, United States (Apr. 2005). [cited by applicant]
Lichtenberger, B.M., et al., “Epidermal Egfr Controls Cutaneous Host Defense and Prevents Inflammation,” Science Translational Medicine 5(199):1-13, American Association for the Advancement of Science, United States (Au… [cited by applicant]
Liesveld, J.L., et al., “Expression of IgG Fc Receptors in Myeloid Leukemic Cell Lines. Effect of Colony-stimulating Factors and Cytokines,” Journal of Immunology 140(5):1527-1533, American Association of Immunologists,… [cited by applicant]
Liu, C and Lee, A., “ADCC Enhancement Technologies for Next Generation Therapeutic Antibody,” Trends in Bio/Pharmaceutical Industry, 9 pages, 2009. [cited by applicant]
Liu, M.A., et al., “Heteroantibody Duplexes Target Cells for Lysis by Cytotoxic T Lymphocytes,” Proceedings of the National Academy of Sciences of the United States of America 82(24):8648-8652, National Academy of Scien… [cited by applicant]
Loffler, A., et al., “A Recombinant Bispecific Single-chain Antibody, CD19 X CD3, Induces Rapid and High Lymphoma-directed Cytotoxicity by Unstimulated T Lymphocytes,” Blood 95(6):2098-2103, American Society of Hematolo… [cited by applicant]
Logtenberg, T., “Hub for Organoids”, Poster Presentation, www.innovationforhealth.nl/index.php/page/getFileUID/id/82364b177dfed9754d785aafffb21363/cr_usedb/25, 29 pages, Mar. 22, 2016. [cited by applicant]
Lotenberg, T., “Hub for organoids can we take it beyond the buzz” Retrieved from Internet: (https://www.innovationtorhealth.nl/index.php/page/getFileUIDIuid/82364b177dfed9754d785aafffb21363/crusedb/25). [cited by applicant]
Luo, H., et al., “Noninvasive Brain Cancer Imaging With a Bispecific Antibody Fragment, Generated via Click Chemistry,” Proceedings of the National Academy of Sciences of the United States of America 112(41):12806-12811… [cited by applicant]
Ma, P.C., et al., “C-Met: Structure, Functions and Potential for Therapeutic Inhibition,” Cancer and Metastasis Reviews 22:309-325, Kluwer Academic, Netherlands (Dec. 2003). [cited by applicant]
Malm, M., et al., “Engineering of a Bispecific Affibody Molecule Towards HER2 and HER3 by Addition of an Albumin-Binding Domain Allows for Affinity Purification and in Vivo Half-Life Extension,” Biotechnology Journal 9(… [cited by applicant]
Marshall, A.S., et al., “Identification and Characterization of a Novel Human Myeloid Inhibitory C-type Lectin-like Receptor (MICL) That is Predominantly Expressed on Granulocytes and Monocytes,” The Journal of Biologic… [cited by applicant]
Maulik, G., et al., “Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition,” Cytokine & Growth Factor Reviews 13(1):41-59, Elsevier Science, United Kingdom (Feb. 2… [cited by applicant]
Maussang ., et al., “The Binding Mode of the Bispecific Anti-Her2xHer3 antibody MCLA-128 is Responsible for its Potent Inhibition of HRG-Driven Tumorigenesis,” Research Poster Presentation Design, 2001, Apr. 1, 2017, Re… [cited by applicant]
May, C., et al., “Advances in Bispecific Biotherapeutics for the Treatment of Cancer,” Biochemical Pharmacology 84:1105-1112, Elsevier, Netherlands (Nov. 2012). [cited by applicant]
McDonagh, C.F., et al., “Antitumor Activity of a Novel Bispecific Antibody that Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3,” Molecular Cancer Therapeutics 11(3):582-593, Am… [cited by applicant]
Merlino, G.T., et al., “Amplification and Enhanced Expression of the Epidermal Growth Factor Receptor Gene in A431 Human Carcinoma Cells,” Science 224(4647): 417-419, American Association for the Advancement of Science,… [cited by applicant]
Merten, H., et al., “Antibody-drug Conjugates for Tumor Targeting-novel Conjugation Chemistries and the Promise of Non-IgG Binding Proteins,” Bioconjugate Chemistry 26(11):2176-2185, American Chemical Society, United St… [cited by applicant]
Merus, www.merus.nl, press release, 2 pages, dated Jan. 7, 2013. [cited by applicant]
Merus, www.merus.nl, press release, 3 pages, dated Jun. 17, 2013. [cited by applicant]
Momeny, M., et al., “Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines,” Oncotarget 6(6):3932-3946, Impact Journal… [cited by applicant]
Moores, S.L., et al., “A Novel Bispecific Antibody Targeting EGFR and cMet is Effective against EGFR Inhibitor-Resistant Lung Tumors,” Cancer Research 76(13):3942-3953, American Association for Cancer Research, United S… [cited by applicant]
Morgillo, F., et al., “Mechanisms of resistance to EGFR targeted drugs: lung cancer,” ESMO Open 2016 1:e000060, 13 pages, Biomedical Journal, United States (May 2016). [cited by applicant]
Stancovski, I., et al., “Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth,” Proceedings of the National Academy of Sciences USA 88(19):8691-8695, National Academ… [cited by applicant]
Morrison, M.M., et al., “ErbB3 Downregulation Enhances Luminal Breast Tumor Response to Antiestrogens,” The Journal of Clinical Investigation 123(10):4329-4343, American Society for Clinical Investigation, United States… [cited by applicant]
Mosmi, S., et al., “Role of MetMAb (OA-5D5) in c-MET Active Lung Malignancies,” Expert Opinion on Biological Therapy 11(12):1655-1662, Taylor & Francis, United Kingdom (Dec. 2011). [cited by applicant]
Mullard, A., et al., “Maturing Antibody-drug Conjugate Pipeline Hits 30,” Nature Reviews Drug Discovery 12(5):329-332, Nature Publishing Group, United Kingdom (May 2013). [cited by applicant]
Musolino, A., et al., “Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-based Therapy in Patients With Her-2/neu-positive Metastatic Breast Cancer,” Journal of Clinical Oncology 26… [cited by applicant]
Nakade, J., et al., “Triple Inhibition of EGFR, MET, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation,” Journal of Thoracic Oncology 9(6):775-783, Elsevier, Unite… [cited by applicant]
Nieba, L., et al., “Disrupting the Hydrophobic Patches at the Antibody Variable/constant Domain Interface: Improved in Vivo Folding and Physical Characterization of an Engineered Scfv Fragment,” Protein Engineering 10(4… [cited by applicant]
Nissim, A., et al., “Antibody Fragments From a ‘single Pot’ Phage Display Library as Immunochemical Reagents,” The EMBO Journal 13(3):692-698, EMBO Press, Germany (Feb. 1994). [cited by applicant]
Park, N.J., et al., “Measurement of Cetuximab and Panitumumab-Unbound Serum EGFR Extracellular Domain Using an Assay Based on Slow Off-Rate Modified Aptamer (SOMAmer) Reagents,” PloS One 8(8):e71703, Public Library of S… [cited by applicant]
Surati, M., et al., “Role of MetMab (OA-5D5) in c-MET active lung malignancies,” Expert Opinion on Biological Therapy 11(12):1655-1662, Taylor & Francis, United Kingdom (Dec. 2011). [cited by applicant]
Olayioye, M.A., et al., “The ErbB Signaling Network: Receptor Heterodimerization in Development and Cancer,” EMBO Journal 19(13):3159-3167, EMBO Press, Germany (Jul. 2000). [cited by applicant]
Omenn, G.S., et al., “A New Class of Protein Cancer Biomarker Candidates: Differentially-Expressed Splice Variants of ERBB2 (HER2/neu) and ERBB1 (EGFR) in Breast Cancer Cell Lines,” Journal of Proteomics 107:103-112, El… [cited by applicant]
Tanner, M., et al., “Characterization of a Novel Cell Line Established From a Patient With Herceptin-resistant Breast Cancer,” Molecular Cancer Therapeutics 3(12):1585-1592, American Association for Cancer Research, Uni… [cited by applicant]
Thery, J.C., et al., “Resistance to Human Epidermal Growth Factor Receptor Type 2-targeted Therapies,” European Journal of Cancer 50(5):892-901, Elsevier, Netherlands (Mar. 2014). [cited by applicant]
Organ, S.L., et al., “An Overview of the C-Met Signaling Pathway,” Therapeutic Advances in Medical Oncology 3(1 Suppl):S7-S19, Sage, United Kingdom (Nov. 2011). [cited by applicant]
Pan, D.S., et al., “Binding Characteristic of Fully Human Anti-EGFR Monoclonal Antibody to EGFR in Skin Tissues of Different Species of Animals,” Chinese Journal of New Drugs Co. Ltd, 21(1):26-30, China (Jan. 2012). [cited by applicant]
Panke, C., et al., “Quantification of Cell Surface Proteins with Bispecific Antibodies,” Protein Engineering Design and Selection 26(10):645-654, Oxford University Press, United Kingdom (Aug. 2013). [cited by applicant]
Papadea, C., and Check, I.J., “Human Immunoglobulin G and Immunoglobulin G Subclasses: Biochemical, Genetic, and Clinical Aspects,” Critical Reviews in Clinical Laboratory Sciences 27(1):27-58, Informa Healthcare, Unite… [cited by applicant]
Pastore, S., et al., “Erk1/2 Regulates Epidermal Chemokine Expression and Skin Inflammation,” Journal of Immunology 174:5047-5056 (Apr. 2005). [cited by applicant]
Patel, D.K., “Clinical Use of Anti-epidermal Growth Factor Receptor Monoclonal Antibodies in Metastatic Colorectal Cancer,” Pharmacotherapy 28(11):31S-41S, Wiley, United States (Nov. 2008). [cited by applicant]
Paul, I., et al., “Current Understanding on EGFR and Wnt/Beta-Catenin Signaling in Glioma and Their Possible Crosstalk,” Genes & Cancer 4(11-12):427-446, Sage, United States (Nov. 2013). [cited by applicant]
Pedersen, M.W., et al., “Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance,” Molecular Cancer Therapeutics 14(3):669-680, American Association for Cancer Research… [cited by applicant]
Wadhwa, D., et al., “Trastuzumab Mediated Cardiotoxicity in the Setting of Adjuvant Chemotherapy for Breast Cancer: a Retrospective Study,” Breast Cancer Research and Treatment 117(2):357-364, Kluwer Academic, Netherlan… [cited by applicant]
Wehrman, T.S., et al., “A System for Quantifying Dynamic Protein Interactions Defines a Role for Herceptin in Modulating ErbB2 Interactions,” Proceedings of the National Academy of Sciences of the United States of Ameri… [cited by applicant]
Wick, M.J., et al., “Establishment and Characterization of a HER2-positive, TDM1-Resistant PDX Breast Model,” Abstract C74 at AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Nov. 5-9,… [cited by applicant]
Troise, F., et al., “A novel ErbB2 epitope targeted by human antitumor immunoagents,” FEBS Journal 278:1156-1166, John Wiley & Sons, United States (Apr. 2011). [cited by applicant]
Prigent, S., et al., “Identification of C-erbB-3 Binding Sites for Phosphatidylinositol 3′-kinase and SHC Using an EGF Receptor/c-erbB-3 Chimera,” The EMBO Journal 13(12):2831-2841, National Center for Biotechnology Inf… [cited by applicant]
Raffen, R., et al., “Reengineering Immunoglobulin Domain Interactions by Introduction of Charged Residues,” Protein Engineering 11(4):303-309, Oxford University Press, United Kingdom (Apr. 1998). [cited by applicant]
Regina, A., et al., “ANG4043, a Novel Brain-Penetrant peptide-mAb Conjugate, is Efficacious Against HER2-positive Intracranial Tumors in Mice,” Molecular Cancer Therapeutics 14(1):129-140, American Association for Cance… [cited by applicant]
Richards, D.A., et al., “A Phase 1 Study of Mm-111, a Bispecific HER2/HER3 Antibody Fusion Protein, Combined with Multiple Treatment Regimens in Patients with Advanced HER2-Positive Solid Tumors,” Journal of Clinical On… [cited by applicant]
Ridgway, J.B., et al., “Knobs-Into-Holes' Engineering of Antibody CH3 Domains for Heavy Chain Heterodimerization,” Protein Engineering 9(7):617-621, Oxford University Press, United Kingdom (Jul. 1996). [cited by applicant]
Riemer, A.B., et al., “Matching of Trastuzumab (Herceptin) Epitope Mimics Onto the Surface of Her-2/neu-a New Method of Epitope Definition,” Molecular Immunology 42(9):1121-1124, Pergamon Press, United Kingdom (May 2005… [cited by applicant]
Robertson, S.C., et al., “RTK mutations and human syndromes: when good receptors turn bad,” Trends in Genetics 16(6):368, Elsevier Science Publishers B.V, United Kingdom (Jun. 2000). [cited by applicant]
Robinson, M.K., et al., “Targeting ErbB2 and ErbB3 with a bispecific single-chain FV Enhances targeting selectivity and induces a therapeutic effect in Vitro”, British Journal of CA 99(9):1415-1425, Nature Publishing Gr… [cited by applicant]
Roskoski, R., “The ErbB/HER Family of Protein-Tyrosine Kinases and Cancer,” Pharmacological Research 79:34-74, Elsevier, Netherlands (Jan. 2014). [cited by applicant]
Sandercock, A.M., et al., “Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling,” Mol Cancer 14:147, BioMed Central Ltd, United Kingdom… [cited by applicant]
Wang, X. Z., et al., “γ-heregulin is the product of a chromosomal translocation fusing the DOC4 and HGL/NRG1 genes in the MDA-MB-175 breast cancer cell line,” Oncogene 18(41):5718-5721, Nature Publishing Group, United K… [cited by applicant]
Geuijen, C., et al., “Preclinical Activity of MCLA-128, an ADCC Enhanced Bispecific IgG1 Antibody Targeting the HER2:HER3 Heterodimer,” Journal of Clinical Oncology 32(15):560-560, Netherlands (May 2014). [cited by applicant]
Howarth, K.D., et al., “NRG1 fusions in breast cancer,” Breast Cancer Res 23(1):3, BioMed Central, United Kingdom (Jan. 2021). [cited by applicant]
Shin, D.H., et al., “Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung,” Oncotarget 7(43):69450-69465, Impact Journals, United States (Oct. 2016). [cited by applicant]
Schmidt, M., et al., “High-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR),” Nat Methods 4(12):1051-1057, Springer Nature, Germany (Dec. 2007). [cited by applicant]
U.S. Appl. No. 18/449,460, Throsby, M., et al., filed Aug. 14, 2023 (Not Published). [cited by applicant]